The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

NovoCure’s Optune Lua, a wearable indicated for patients with metastatic non-small cell lung cancer has received approval ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Aspirin did not impact CVD incidence; however, risk may be higher in those with metastatic, hematological and lung cancer and ...

SAN ANTONIO, October 16, 2024--bioAffinity VP served on expert panel to update flow cytometry guidelines for unique ...

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...